Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036758 · ClinicalTrials.gov registry record
VIDAS® NEPHROCLEAR Diagnostic Accuracy Study
A clinical trial, sponsored by BioMérieux.
- Completed
- Registry status
- 477
- Enrollment target
NCT06036758: Completed study, sponsored by BioMérieux.
NCT06036758 is a clinical trial that has completed, run by BioMérieux. The registered enrollment target is 477 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06036758 has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- 477 participants
- Enrollment target
Study Summary
This is a multi-center sample analysis study in which urine samples previously collected from persons with Stage 2 or Stage 3 Acute Kidney Injury (AKI), will be tested in order to validate the VIDAS® NEPHROCLEAR™ CCL14 Test
Primary Outcome
The urine sample collected from ICU patients will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test, which is intended to be used in conjunction with clinical evaluation, in ICU patients with moderate to severe (stage 2 or 3) acute kidney injury (AKI), as an aid in the risk assessment for developing persistent severe AKI (stage 3 AKI lasting ≥ 72 hours) within 48 hours of patient assessment
Interventions
- DIAGNOSTIC_TEST VIDAS® NEPHROCLEAR™ CCL14 Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2023-12-28 |
What the finished NCT06036758 record still lists
NCT06036758 is an observational study that tracks outcomes without assigning an intervention. The registered 477 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which VIDAS® NEPHROCLEAR™ CCL14 Test is the first listed.
NCT06036758 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06036758 about?
NCT06036758 is a clinical study titled "VIDAS® NEPHROCLEAR Diagnostic Accuracy Study". This is a multi-center sample analysis study in which urine samples previously collected from persons with Stage 2 or Stage 3 Acute Kidney Injury (AKI), will be tested in order to validate the VIDAS® NEPHROCLEAR™ CCL14 Test
What is the current status of trial NCT06036758?
This trial is currently completed. The enrollment target is 477 participants. The study started on 2023-07-17. Estimated completion is 2023-12-28.
What interventions are being tested in trial NCT06036758?
The interventions under investigation include: VIDAS® NEPHROCLEAR™ CCL14 Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06036758?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI